Home Ingredients Microcrystalline Hydroxyapatite (MCHA / MCH)
Bone Health

Microcrystalline Hydroxyapatite (MCHA / MCH)

Evidence Level
Moderate
2 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

Microcrystalline hydroxyapatite (MCHA, also called ossein-hydroxyapatite complex / OHC) is calcium derived from BOVINE BONE — providing calcium AND phosphorus AND collagen-derived organic matrix in the same compound found in human bone. Some studies suggest superior bone-building effects vs calcium carbonate or citrate. More expensive; animal-derived (not vegetarian/vegan); quality varies significantly by source.

Studied Dose 1,000-2,000 mg MCHA/day (provides ~250-500 mg elemental calcium plus phosphorus and collagen peptides)
Active Compound Microcrystalline hydroxyapatite (Ca10(PO4)6(OH)2 + organic matrix)

Benefits

Bone-Identical Mineral Form

Hydroxyapatite (Ca10(PO4)6(OH)2) is the actual mineral structure of human bone and tooth enamel. MCHA provides calcium and phosphorus in the same crystalline form found in bone — proposed advantage for bone matrix incorporation.

Supported by Trial 1

Postmenopausal Bone Density (Some Evidence)

Several trials suggest MCHA produces equal-or-better BMD effects vs calcium carbonate or citrate in postmenopausal women. Castelo-Branco et al. trials and Pelayo et al. 2007 four-year follow-up support efficacy. Not consistently superior in head-to-head comparisons.

Supported by Trial 1, Trial 2

Phosphorus Content

MCHA provides phosphorus alongside calcium — bone needs both. Most calcium supplements lack phosphorus; MCHA's phosphorus content matches bone composition.

Supported by Trial 1

Organic Matrix Components

MCHA contains residual collagen-derived peptides, growth factors (theoretically), and trace elements from bone matrix — distinct from simple inorganic calcium salts.

Supported by Trial 1

Slow Calcium Release

Hydroxyapatite has lower acute solubility than calcium carbonate or citrate — leads to smaller transient calcium spikes. Some practitioners propose this is more physiological.

Supported by Trial 1

Mechanism of action

1

Hydroxyapatite Crystal Structure

Calcium phosphate crystallized as Ca10(PO4)6(OH)2 — the identical mineral structure of bone hydroxyapatite. Slowly dissolves in stomach to release Ca²⁺ and phosphate ions for absorption.

2

Phosphorus + Calcium Combined

Bone is ~99% hydroxyapatite (calcium phosphate) — providing both minerals together is theoretically more physiologic than calcium-only supplementation.

3

Slower Absorption

Lower acute solubility means slower calcium release vs carbonate/citrate — smaller serum calcium spikes; some practitioners consider this safer for cardiovascular concerns about calcium supplementation.

4

Bovine Bone Source Variability

MCHA quality varies significantly by source — bovine origin (concerns about BSE/prion contamination, pesticide exposure, antibiotic residues), processing methodology, and standardization. New Zealand-sourced MCHA is generally considered higher-quality.

Clinical trials

1
MCHA vs Calcium Citrate vs Carbonate — Castelo-Branco 2014
PubMed

RCT comparing acute and 3-month effects of MCHA, calcium citrate, and calcium carbonate on serum calcium and bone turnover markers in postmenopausal women.

Postmenopausal women.

MCHA produced smaller serum calcium AUC vs citrate/carbonate (slower absorption) but similar effect on bone turnover markers. PTH suppression less pronounced with MCHA — interpreted as more physiological pattern. Not directly superior on hard outcomes.

2
Ossein-Hydroxyapatite Complex 4-Year Follow-Up — Pelayo 2007
PubMed

Four-year follow-up of OHC supplementation for osteoporosis prevention in postmenopausal women.

Postmenopausal women.

MCHA/OHC supported BMD maintenance over 4 years. Industry-funded research; not direct comparison to bisphosphonates (which are gold-standard pharmacotherapy for osteoporosis).

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated.
Larger pills (lower elemental calcium content per gram of MCHA).
Constipation — less than calcium carbonate but still possible.
ANIMAL SOURCE concerns — BSE/prion (resolved with reputable sources), pesticide exposure, antibiotic residues.
Cost — substantially more expensive than carbonate or citrate.
Religious/dietary restrictions — bovine-derived; not vegetarian/vegan; may not be kosher/halal depending on source/processing.

Important Drug interactions

Same general calcium drug interactions — tetracyclines, quinolones, bisphosphonates, levothyroxine, iron; separate by 2-4 hours.
Phosphorus content — important for renal patients; CKD often requires phosphorus restriction; AVOID MCHA in late-stage CKD.
Aluminum-containing drugs — separate.
Thiazide diuretics — hypercalcemia risk.
Featured In

Symptom-specific supplement guides

🦴Best Supplements for Bone Density🌸Best Supplements for Menopause

More Bone Health Ingredients

Bone Health
Calcium
Calcium is the most abundant mineral in the body — about 99% stored in bones and teeth, wi…
Bone Health
Vitamin D
Vitamin D is a fat-soluble vitamin and steroid hormone precursor essential for calcium abs…
Bone Health
Copper
Copper is an essential trace mineral and cofactor for over 30 enzymatic reactions, includi…
Bone Health
Ferrous Sulfate
Ferrous sulfate is the most common, cheapest, and longest-established oral iron form — rec…

Frequently asked questions about Microcrystalline Hydroxyapatite (MCHA / MCH)

What is Microcrystalline Hydroxyapatite (MCHA / MCH)?

Microcrystalline hydroxyapatite (MCHA, also called ossein-hydroxyapatite complex / OHC) is calcium derived from BOVINE BONE — providing calcium AND phosphorus AND collagen-derived organic matrix in the same compound found in human bone.

What does Microcrystalline Hydroxyapatite (MCHA / MCH) do?

Calcium phosphate crystallized as Ca10(PO4)6(OH)2 — the identical mineral structure of bone hydroxyapatite. Slowly dissolves in stomach to release Ca²⁺ and phosphate ions for absorption. In clinical research, Microcrystalline Hydroxyapatite (MCHA / MCH) has been studied for bone-identical mineral form, postmenopausal bone density (some evidence), phosphorus content.

Who should take Microcrystalline Hydroxyapatite (MCHA / MCH)?

Microcrystalline Hydroxyapatite (MCHA / MCH) may be most relevant for people interested in bone health. It has been clinically studied for bone-identical mineral form, postmenopausal bone density (some evidence), phosphorus content. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Microcrystalline Hydroxyapatite (MCHA / MCH) take to work?

Most clinical trial effects appear over weeks of consistent use; individual response varies. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Microcrystalline Hydroxyapatite (MCHA / MCH)?

Microcrystalline Hydroxyapatite (MCHA / MCH) can typically be taken with breakfast or dinner — taking with food reduces GI sensitivity for most supplements. Specific timing matters less than daily consistency for cumulative effects. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Microcrystalline Hydroxyapatite (MCHA / MCH) worth taking?

Microcrystalline Hydroxyapatite (MCHA / MCH) has moderate clinical evidence (Evidence Level 3/5 on NutraSmarts) — meaningful trial support exists, though results are less consistent than top-tier ingredients. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Microcrystalline Hydroxyapatite (MCHA / MCH) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Microcrystalline Hydroxyapatite (MCHA / MCH)?

The clinically studied dose for Microcrystalline Hydroxyapatite (MCHA / MCH) is 1,000-2,000 mg MCHA/day (provides ~250-500 mg elemental calcium plus phosphorus and collagen peptides). Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Microcrystalline Hydroxyapatite (MCHA / MCH) used for?

Microcrystalline Hydroxyapatite (MCHA / MCH) is studied for bone-identical mineral form, postmenopausal bone density (some evidence), phosphorus content. Hydroxyapatite (Ca10(PO4)6(OH)2) is the actual mineral structure of human bone and tooth enamel. MCHA provides calcium and phosphorus in the same crystalline form found in bone — proposed advantage for bone matrix incorporation.